報價延遲最少15分鐘:2025/07/17 22:56 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
8.7 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.04/-21.75
|
|
企業價值
5.02M
|
| 資產負債 |
|
每股賬面淨值
-5.34
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/07/17 22:56 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables itto integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand. |
